Global Genomic Data-as-a-Service (GDaaS) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Genomic Data-as-a-Service (GDaaS) Market Size

• The global Genomic Data-as-a-Service (GDaaS) market size was valued at USD 841.8 million in 2024 and is expected to reach USD 6,659.16 million by 2032, at a CAGR of 29.50% during the forecast period
• This growth is driven by factors such as the rising demand for personalised medicine, advancements in genomic technologies and expanding applications in healthcare

Genomic Data-as-a-Service (GDaaS) Market Analysis

• Genomic Data-as-a-Service (GDaaS) is a critical solution that enables the storage, analysis, and sharing of large-scale genomic data, supporting research, precision medicine, drug discovery, and population health studies. It provides researchers and healthcare professionals with high-throughput, real-time access to complex genetic information
• The demand for GDaaS is significantly driven by the increasing adoption of personalized medicine, advancements in next-generation sequencing (NGS) technologies, and the growing need for large-scale data analytics in genomics
• North America is expected to dominate the Genomic Data-as-a-Service (GDaaS) market with a market share of 47.6% driven by advanced healthcare infrastructure, high adoption of cutting-edge genomic technologies, and a strong presence of key market players
• Asia-Pacific is expected to be the fastest growing region in the Genomic Data-as-a-Service (GDaaS) market with a market share of 26.9% driven by rapid expansion in healthcare infrastructure, increasing awareness about personalized medicine, and rising demand for genetic testing
• Next-generation sequencing (NGS) segment is expected to dominate the market with a market share of 58.6%, due to its ability to rapidly and accurately sequence entire genomes, transcriptomes, and targeted regions at a fraction of the cost and time of traditional methods

Report Scope and Genomic Data-as-a-Service (GDaaS) Market Segmentation

Genomic Data-as-a-Service (GDaaS) Market Trends

“Advancements in Genomic Data-as-a-Service (GDaaS) for Precision Medicine and Research”

• One prominent trend in the evolution of the Genomic Data-as-a-Service (GDaaS) market is the increasing integration of artificial intelligence (AI) and cloud computing for large-scale genomic data analysis
• These innovations enhance data processing speed and accuracy, allowing researchers and healthcare professionals to derive meaningful insights from complex genetic datasets, ultimately improving patient outcomes and accelerating drug discovery 
  • For instance, modern GDaaS platforms utilize AI algorithms for rapid variant detection, predictive modeling, and personalized treatment recommendations, which are particularly beneficial for precision medicine and population genomics studies
• These advancements are transforming the genomics landscape, reducing the time and cost of genetic analysis, and driving the demand for next-generation GDaaS solutions with cutting-edge analytical capabilities

Genomic Data-as-a-Service (GDaaS) Market Dynamics

Driver

“Rising Demand for Personalized Medicine and Precision Healthcare”

• The growing focus on personalized medicine and precision healthcare is significantly contributing to the increased demand for Genomic Data-as-a-Service (GDaaS) solutions
• As healthcare shifts toward more targeted therapies, the ability to analyze and interpret large volumes of genomic data has become critical for accurate diagnostics, disease risk assessment, and tailored treatment plans
• The increasing prevalence of chronic and genetic disorders further drives the need for advanced genomic data solutions, enabling healthcare providers to deliver more precise and effective care

For instance,

• In March 2025, according to an article published in the Nature Medicine journal, the demand for personalized medicine is expected to grow significantly, with precision oncology alone projected to account for nearly 40% of the total cancer therapy market by 2030. This surge in demand for personalized treatments highlights the critical role of genomic data in developing targeted therapies for cancer and other complex diseases 
• As a result, the demand for GDaaS is expected to rise, supporting the shift towards precision healthcare and improving patient outcomes

Opportunity

“Leveraging Artificial Intelligence for Advanced Genomic Data Analysis”

• AI-powered GDaaS platforms can enhance data processing, automate variant detection, and improve the accuracy of genomic insights, enabling researchers and healthcare professionals to make more informed decisions
• AI algorithms can analyze large-scale genomic datasets in real time, identifying genetic mutations, predicting disease risks, and supporting personalized treatment strategies
• In addition, AI-driven data platforms can also assist in biomarker discovery, drug development, and population genomics studies, providing deeper insights into complex genetic interactions

For instance,

• In January 2025, according to an article published in the Journal of Genomic Medicine, AI-powered genomic data platforms have demonstrated the ability to accurately predict disease progression in patients with rare genetic disorders, significantly reducing diagnostic delays and improving patient outcomes. This capability is transforming the field of genomics, providing critical insights into disease mechanisms and personalized treatment options 
• The integration of AI in GDaaS platforms is expected to drive market growth by reducing analysis time, improving diagnostic accuracy, and enhancing overall healthcare outcomes

Restraint/Challenge

“Data Privacy and Security Concerns Hindering Market Growth”

• Data privacy and security concerns pose a significant challenge for the GDaaS market, as genomic data is highly sensitive and requires strict regulatory compliance
• The risk of data breaches, unauthorized access, and misuse of genetic information can deter healthcare providers and researchers from adopting GDaaS solutions
• In addition, the complexity of managing and securing large-scale genomic datasets adds to the operational challenges for service providers

For instance,

• In November 2024, according to an article published by the Healthcare Information and Management Systems Society (HIMSS), the increasing number of cyberattacks targeting healthcare data, including genomic information, has raised concerns about data security and patient privacy. This has prompted regulators to impose stricter data protection requirements, adding to the operational costs and compliance challenges for GDaaS providers 
• Consequently, these concerns may slow down market adoption, limit data sharing, and hinder the overall growth of the GDaaS market

Genomic Data-as-a-Service (GDaaS) Market Scope

The market is segmented on the basis of service type, technology, application, and end user.

In 2025, the next generation sequencing (NGS) is projected to dominate the market with a largest share in service type segment

The next-generation sequencing (NGS) segment is expected to dominate the GDaaS market with the largest share of 58.6% due to its ability to rapidly and accurately sequence entire genomes, transcriptomes, and targeted regions at a fraction of the cost and time of traditional methods. NGS can sequence millions of DNA fragments simultaneously, enabling large-scale genomic studies and diagnostics in hours or days, compared to weeks for older methods such as Sanger sequencing.

The personalized medicine is expected to account for the largest share during the forecast period in application market

In 2025, the personalized medicine segment is expected to dominate the market with the largest market share of 36.40% due to its high prevalence and demand for precision. The increasing adoption of precision healthcare, driven by advancements in genomic technologies, is expected to enhance the demand for personalized medicine, further solidifying its dominance in the GDaaS market. The growing need for personalized treatments is a key factor contributing to its market leadership.

Genomic Data-as-a-Service (GDaaS) Market Regional Analysis

“North America Holds the Largest Share in the Genomic Data-as-a-Service (GDaaS) Market”

• North America dominates the Genomic Data-as-a-Service (GDaaS) market by 47.6%, driven by advanced healthcare infrastructure, high adoption of cutting-edge genomic technologies, and a strong presence of key market players
• U.S. holds a significant share 35.5% due to the growing demand for precision medicine, increasing prevalence of genetic disorders, and continuous advancements in genomic technologies
• The availability of well-established healthcare policies, such as insurance coverage for genetic testing and treatments, along with growing investments in research and development by leading biotech companies, further strengthens the market
• In addition, the rising demand for personalized healthcare solutions and the development of innovative drug discovery platforms are fueling market growth across the region

“Asia-Pacific is Projected to Register the Highest CAGR in the Genomic Data-as-a-Service (GDaaS) Market”

• Asia-Pacific is expected to witness the highest growth rate with market share of 26.9% in the Genomic Data-as-a-Service (GDaaS) market, driven by rapid expansion in healthcare infrastructure, increasing awareness about personalized medicine, and rising demand for genetic testing
• Countries such as China, India, and Japan are emerging as key markets due to their growing aging populations, which are more susceptible to genetic disorders such as cancer, diabetes, and cardiovascular diseases
• Japan, with its advanced healthcare system and increasing adoption of genomic technologies in clinical practices, remains a crucial market for GDaaS solutions. The country is at the forefront of adopting AI and big data analytics to drive precision medicine and genetic research
• India is projected to register the highest CAGR in the GDaaS market, fueled by expanding healthcare infrastructure, government initiatives to promote health awareness, and the rising prevalence of genetic conditions. The country's increasing investment in biotechnology and healthcare research further contributes to its growth in the genomic data services market

Genomic Data-as-a-Service (GDaaS) Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Qiagen (Germany)
• Agilent Technologies, Inc. (U.S.)
• PacBio (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• PerkinElmer (U.S.)
• Oxford Nanopore Technologies plc. (U.K.)
• Genomics England (U.K.)
• DiaSorin S.p.A. (Italy)
• BD (U.S.)
• Illumina, Inc. (U.S.)
• Medtronic (Ireland)
• Promega Corporation (U.S.)
• Bio-Techne (U.S.)

Latest Developments in Global Genomic Data-as-a-Service (GDaaS) Market

• In January 2025, Illumina, Inc., a leader in genomics, announced the launch of its new NovaSeq 6000 System, designed to enhance sequencing performance with improved throughput and accuracy for genomic research. The system leverages advanced technology to accelerate the pace of genomic discovery, enabling faster and more cost-effective sequencing for applications such as personalized medicine, cancer research, and genetic disease diagnostics. The NovaSeq 6000's scalable design offers unmatched flexibility, making it ideal for a broad range of research needs from clinical diagnostics to large-scale genome studies
• In October 2024, Thermo Fisher Scientific presented new developments at the American Society of Human Genetics (ASHG) 2024 conference, including the release of its Ion Proton System, which offers high-throughput next-generation sequencing (NGS) capabilities for precision medicine. This new technology aims to reduce sequencing costs and improve turnaround times, enabling faster clinical diagnostics and more accurate genomic profiling for patients with inherited genetic disorders
• In September 2024, Qiagen N.V. announced the launch of its new QIAseq Targeted RNA Panels for precision oncology. The panels, designed for accurate and efficient RNA sequencing, will help researchers and clinicians identify genetic mutations and biomarkers in cancer patients, improving the ability to make informed treatment decisions based on genetic profiles. These panels offer higher sensitivity and better coverage, ensuring reliable results even from challenging and low-input samples
• In September 2024, Oxford Nanopore Technologies unveiled its GridION X5, a new benchtop device that allows for high-throughput sequencing with real-time results. The GridION X5 offers genomic researchers the flexibility to perform sequencing in a variety of applications, from large-scale genomic studies to point-of-care diagnostics. The system features improved data accuracy and scalability, allowing researchers to adapt their workflows to meet the growing demand for genomic testing and analysis

SKU-74034